Flow Traders U.S.’s Revelation Biosciences Warrant REVBW Stock Holding History

Flow Traders U.S.’s Portfolio REVBW Stock Details REVBW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,566	Closed	–	–	1061
2023 Q1	$0	Buy	15,566 +407	+3%	+$10	﹤0.01%	1087
2022 Q4	$0	Buy	+15,159	New	+$482	﹤0.01%	1082
2022 Q3	–	Sell	-11,081	Closed	-$1K	–	1200
2022 Q2	$1K	Buy	+11,081	New	+$929	﹤0.01%	790

Other funds holding REVBW

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

PVI

Pine Valley Investments Marlton, New Jersey $2.18B AUM 26.57% 1-Year Est. Return

Flow Traders U.S.'s REVBW Position: Q2 2023 in Review

Flow Traders U.S. sold out of Revelation Biosciences Warrant (REVBW) in Q2 2023, closing a stake of 15,566 shares.

Flow Traders U.S. first reported a position in REVBW in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q2 2022. 12 funds tracked by Wall St. Rank hold REVBW as of Q2 2023.

Flow Traders U.S. reported no remaining Revelation Biosciences Warrant position as of Q2 2023 after selling out during the quarter.
Flow Traders U.S. sold 15,566 Revelation Biosciences Warrant shares in Q2 2023.
Flow Traders U.S. first reported a position in Revelation Biosciences Warrant in Q2 2022 and held it in 3 quarters.
Flow Traders U.S.'s Revelation Biosciences Warrant position peaked at $1K in Q2 2022.
12 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q2 2023.

Based on Flow Traders U.S.'s 13F filing for Q2 2023, filed 9 Aug 2023.